Theriva Biologics, Inc. · AMEX:TOVX

Theriva Biologics — Investor Presentation (November 2023)

42 slides from Theriva Biologics's investor presentation, Nov 1, 2023

  1. Slide 1: Corporate Overview

    Corporate Overview © Theriva BIOLOGICS

  2. Slide 2: Forward Looking Statements

    FORWARD LOOKING STATEMENTS This presentation includes forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. In some cases forward- looking statements can be identified by terminology such as "may," "should," "potential," "continue," "expects," "antici

  3. Slide 3: Overview

    OVERVIEW ° Theriva Biologics is developing unique oncolytic viruses optimized for systemic administration Financial Snapshot Exchange NYSE American ° VCN-01 is undergoing a Phase 2b clinical trial in Ticker Tovx first-line metastatic pancreatic cancer in Cash (6/30/2023) $34.2M combination with SoC

  4. Slide 4: Management team

    Steven Shallcross Manel Cascalló PhD Vince Wacher PhD Chief Executive Officer, Chief General Director, EU Subsidiary Head Corporate Development Financial Officer Expertise in oncolytic adenovirus Nearly 30 years leading corporate Served as the Company’s CEO since clinical development, received strat

  5. Slide 5: Pipeline

    Candidate Target Pre-IND Phase 1 Phase 2 Collaborators Status* Pancreatic Cancer (IV) with Phase 2 Study On-going gemcitabine/nab-paclitaxel (ODD EU, US) Phase1 Study On-going Retinoblastoma (IVit) (ODD US) VCN-01 Selective, Stroma Degrading OV Phase 1 Treatment Complete HNSCC (IV) + durvalumab Surv

  6. Slide 6: VCN-01 is a uniquely engineered human adenovirus

    VCN-01 IS A UNIQUELY ENGINEERED HUMAN ADENOVIRUS 5 Access primary and metastatic lesions Systemic High dose, highly replicating Replicates only in tumor cells Selective Liver detargeted Expresses PH20 (hyaluronidase) after viral replication cycle Stroma Degrading PH20 in blood is a biomarker for vir

  7. Slide 7: VCN-01 designed to have multiple anti-tumor actions

    VCN-01 DESIGNED TO HAVE MULTIPLE ANTI-TUMOR ACTIONS SELECTIVE replication at high levels lyses tumor cells directly without harming healthy tissues Tumor Surrounded by STROMA VCN-01 VCN-01 BIOLOGICS

  8. Slide 8: VCN-01 designed to have multiple anti-tumor actions

    VCN-01 DESIGNED TO HAVE MULTIPLE ANTI-TUMOR ACTIONS STROMA DEGRADATION by PH20 facilitates tumor COMBINED EFFECTS increase tumor immunogenicity access and killing by coadministered cancer therapies and elicit an anti-tumor immune response ge nab-paclitaxel coy gemcitabine Who VCN-01 VCN-01 —_ > e ©

  9. Slide 9: VCN-01 extensive Phase program

    VCN-01 EXTENSIVE PHASE 1 PROGRAM 84 patients treated in multiple indications and combinations Sart Joan de Dew Lead Indication for Phase 2 PANCREATIC - IV “4 COLORECTAL - IV (+ Gemcitabine / Abraxane®) 4 (alone) BRAIN TUMORS - IV (alone)* UNIVERSITY OF LEEDS PANCREATIC - IT HEAD & NECK - IV (alone)

  10. Slide 10: VCN-01 Phase Program in Pancreatic Cancer

    @ Theriva VCN-01 PHASE 2 PROGRAM IN PANCREATIC CANCER

  11. Slide 11: VCN-01 lead indication pancreatic cancer

    VCN-01 LEAD INDICATION PANCREATIC CANCER Highly fatal cancer protected by dense tumor stroma * Orphan disease with the highest mortality of all solid tumors * Median survival 8-11 months for metastatic disease’ ° USA est. 62,210 new cases and 49,830 deaths in 202223 ° Hyaluronic acid in stroma is as

  12. Slide 12: VCN-01 favorable outcomes in Phase 1 trial

    VCN-01 FAVORABLE OUTCOMES IN PHASE 1 TRIAL Multicenter, open-label, dose escalation study [NCT02045602] ARM I MONOTHERAPY Solid tumors (16) ARM II CONCOMITANT? PDAC (12) 8 VCN-01 Dose Finding! v Single IV doses of VCN-01 alone or with standard-of-care (SoC) chemotherapy gemcitabine/nab-paclitaxel (A

  13. Slide 13: VCN-01 favorable outcomes in Phase 1 trial

    VCN-01 FAVORABLE OUTCOMES IN PHASE 1 TRIAL Multicenter, open-label, dose escalation study [NCT02045602] 3.3x10" ( Combined (12)| Phase 3 (43 VCN-01 Combined, Sequential Regimen Responders, % 16.7% 83.3% 50.0% Pyrexia/Influenza-like IIIness 12 (85.7%) Median OS, months 13.1 20.8 13.5 8.5 Nausea 3 (21

  14. Slide 14: Phase 1 data support VCN-01 mode-of-action

    PHASE 1 DATA SUPPORT VCN-01 MODE-OF-ACTION Remodels the tumor matrix and turns “cold” tumors “hot” Built-in biomarker: PH20 levels in patient sera Immune markers upregulated in indicate sustained VCN-01 activity in tumors biopsies of hepatic metastases 1200+ VCN-01 1.0x1013 vp (Arms I, Il, III CD8*

  15. Slide 15: VIRAGE Phase 2b clinical trial in PDAC

    VIRAGE PHASE 2B CLINICAL TRIAL in PDAC Multicenter, open-label, randomized, controlled trial (NCT05673811) * Study on-going in patients with first-line metastatic pancreatic ductal adenocarcinoma (PDAC) Up to 92 patients to be enrolled at sites in Spain and the USA (complete enrollment expected H1 2

  16. Slide 16: PDAC treatment landscape and expansion opportunities

    Radiotherapy if increases resection margins’ First-Line pA y Ng Treatments . (m)FOLFIRINOX (ECOG 0-1)* or Gemcitabine + nab-Paclitaxel (ECOG 0-2) y Neoadjuvant? . aan ontie i 5 an or single agent gemcitabine, capecitabine, 5-FU (ECOG 3-4)? ; Topoisomerase inhibitor ! combinations* VCN-O1 \sing Expan

  17. Slide 17: VCN-01 + Immune CPI Phase 1 Data in R/M HNSCC

    @ Theriva VCN-01 + IMMUNE CPI PHASE 1 DATA IN R/M HNSCC

  18. Slide 18: HNSCC study design: concomitant and sequential arms

    ✓ ✓ ✓ VCN-01 3.3x10¹² vp (6) ARM I Durvalumab¹ CONCOMITANT Durvalumab 28-day HNSCC (6) BIOPSY SCR cycles starting Day 29 BIOPSY D8 BIOPSY D28 ARM II VCN-01 3.3x10¹² vp (6), 1x10¹³ vp (8) SEQUENTIAL Durvalumab 28-day HNSCC (14) Durvalumab¹ cycles starting Day 44 BIOPSY SCR BIOPSY D8 BIOPSY D28 | | |

  19. Slide 19: VCN-01 findings in R/M HNSCC

    VCN-01 FINDINGS in R/M HNSCC Data support VCN-01 MOA and immune enhancing effects v¥ VCN-01 has an acceptable safety profile when administered prior to durvalumab (Imfinzi®) v¥ VCN-01 reaches tumors, has sustained replication and PH20 expression v¥ VCN-01 treatment led to downregulation of tumor mat

  20. Slide 20: Overall Survival vs CPS in Biopsies at Day 8

    • Overall Survival vs CPS in Biopsies at Day 8 Spearman r = 0.7676 P (2-tailed) = 0.0050 • •

  21. Slide 21: Next Generation OV Discovery Platform

    @ Theriva NEXT GENERATION OV DISCOVERY PLATFORM

  22. Slide 22: ABD binds serum albumin to form a protective coating

    ™ • OV Parent oncolytic virus (OV) susceptible to neutralizing antibodies • • Albumin binding domain (ABD) OV-ABD expressed on the virus surface (hexon) • • ABD binds serum albumin ⚫ to form a Y OV-ABD coating that protects against neutralizing antibodies Y

  23. Slide 23: Theriva OV pipeline discovery and development

    THERIVA OV PIPELINE DISCOVERY AND DEVELOPMENT Advancing founders’ decade of world leading OV innovation Clinically-tested Adenovirus Expressing PH20 Hyaluronidase to Degrade Stroma + Albumin Shield™ To Prevent Neutralization by anti-viral Antibodies and Facilitate IV Multidosing + Unique Multifuncti

  24. Slide 24: Summary

    @ Theriva SUMMARY

  25. Slide 25: Theriva OV portfolio highlights

    THERIVA OV PORTFOLIO HIGHLIGHTS Multiple modes of action, indications, and combinations * Highly differentiated OV designed to have multiple antitumor effects ; * Systemic administration, selective tumor replication, stroma degradation * Designed to increases cell lysis, tumor immunogenicity, and tu

  26. Slide 26: Projected milestones and news flow

    PROJECTED MILESTONES AND NEWS FLOW * VCN-01 PDAC Phase 2 enrollment complete * VCN-01 HNSCC ISS * VCN-12 candidate survival/efficacy data selection?? * VCN-01 PDAC Phase 2 * VCN-01 FDA meeting * SYN-004 Phase 1b/2a data 1st patients dosed USA retinoblastoma program 2°4 cohort * VCN-01 PDAC Orphan Dr

  27. Slide 27: Financial and investment goals

    FINANCIAL AND INVESTMENT GOALS ° Immediate Goals ¢ Augment share register with additional sophisticated institutional investors ° Establish a realistic share price/valuation to facilitate financial options ° External validation through a funded discovery or development partnership ° Mid- to Longer T

  28. Slide 28: Appendix

    @ Theriva APPENDIX

  29. Slide 29: Intellectual property

    INTELLECTUAL PROPERTY Hyaluronidase OV Albumin Shield™ Oral B-Lactamase Oral IAP VCN-01, VCN-11 VCN-11, Discovery SYN-004, -006, -007 SYN-020 Composition of Matter Composition of Matter Composition of Matter Manufacturing Know- (exp 2030) (exp 2034) (exp 2031-5) how (Trade Secret) Methods of Use and

  30. Slide 30: Extensive VCN-01 Phase 1 clinical experience

    EXTENSIVE VCN-01 PHASE 1 CLINICAL EXPERIENCE >80 Patients Treated in Diverse Cancer Indications Location Phase | Indication Co-therapy te | Status Registry Multicenter (ESP) 1 ea Part |: None Part |: Solid tumor Parts II,IIl: Gemcitabine + IV Complete’ NCT02045602 Part Il, Ill: PDAC nab-Paclitaxel M

  31. Slide 31: Most common IV VCN-01 related AEs

    MOST COMMON IV VCN-01 RELATED AEs [NCT02045602] VERSE EVENTS? Part | (Alone, n=16) Part Il (Concomitant, 12)? Part III (Sequential, 14) Febrile neutropenia 2 (16.7%) Neutropenia/Neutrophil count decreased 2 (12.5%) - 1 (8.3%) 1 (8.3%) - - Thrombocytopenia/Platelet count decreased 1 (6.3%) 1 (6.3%) 3

  32. Slide 32: VIRAGE Phase 2b clinical trial differentiators

    VIRAGE PHASE 2 CLINICAL TRIAL —- DIFFERENTIATORS Vv First-line treatment of metastatic PDAC patients Y Direct comparison with standard-of-care chemotherapy in the same trial ¥Y Open label provides real-time opportunity to review emerging VCN-01 treatment effects Y Interim analysis based on secondary

  33. Slide 33: Adverse reactions by CTCAE grade

    Arm I - Concomitant Arm II - Sequential Arm II - Sequential Adverse Reactions (Dose 3,3E12 , n=6)² (Dose 3,3E12 , n=6)³ (Dose 1E13 , n=8)³ CTCAE Grade Grade 1-2 Grade ≥3 Grade 1-2 Grade ≥3 Grade 1-2 Grade ≥3 Pyrexia 2 (33,0%) - 5 (62,5%) - 3 (50%) - Influenza like illness 3 (50,0%) - 3 (37,5%) 2(25%

  34. Slide 34: OS vs CPS at screening and Day 8

    Pre-treatment Day 8 after VCN-01 dose OS vs CPS SCR OS vs CPS D8 50 50 Spearman r 0.1348 Spearman r 0.7676 P (two-tailed) 0.0050 ** 40 40 OS (months) OS (months) 30 30 20 20 10 10 0 0 0 20 40 60 80 100 0 20 40 60 80 100 CPS score CPS score Initial evidences suggests that VCN-01 induced PD-L1 upregul

  35. Slide 35: Theriva oncolytic viruses key publications

    THERIVA ONCOLYTIC VIRUSES KEY PUBLICATIONS Bayo-Puxan N et al. (2006) Role of the putative heparan sulfate glycosaminoglycar-binding site of the adenovirus type 5 fiber shaft on liver detargeting and knob-mediated retargeting. J Gen Virol 87:2487-2495 Bazan-Peregrino M et al. (2021) VCN-01 disrupts

  36. Slide 36: Pancreatic cancer references

    PANCREATIC CANCER REFERENCES DESCRIPTION, CLASSIFICATION, STAGING, STROMA Balachandran VP et al. (2019) Broadening the impact of immunotherapy to pancreatic cancer: challenges and opportunities. Gastroenterology 156:2056-72 Christenson ES et al. (2020) Current and emerging therapies for patients wit

  37. Slide 37: Retinoblastoma (Rb) references

    RETINOBLASTOMA (Rb) REFERENCES DESCRIPTION, CLASSIFICATION, STAGING American Academy of Ophthalmology. EyeWiki®. Retinoblastoma. https://eyewiki.org/Retinoblastoma American Cancer Society. Key statistics for retinoblastoma. https://www.cancer.org/cancer/retinoblastoma/about/key-statistics.html Cantu

  38. Slide 38: VCN-01 Retinoblastoma

    @ Theriva VCN-01 RETINOBLASTOMA

  39. Slide 39: Retinoblastoma, a rare pediatric malignancy

    Retinoblastoma, a Rare Pediatric Malignancy * Retinoblastoma (Rb) is an orphan indication that accounts for ~2-3% of all childhood cancers! * 200-300 cases each year in the USA, EU2* ° VCN-01 selectivity enables development as an intravitreal treatment for Rb patients * VCN-01 could be used in combi

  40. Slide 40: Promising results in 2 of the patients treated to date

    • Promising Results in 2 of the Patients Treated to date with High Dose VCN-01 • Reduced number and size of tumor vitreous seeds • following VCN-01 administration² • ⁹ Pt 22 • D0 D14 D28 • Pt 3 • D0 D6 M8 4 • Complete tumor regression³

  41. Slide 41: Interim safety data for intravitreal VCN-01

    Interim Safety Data for Intravitreal VCN-01 Two Intravitreal VCN-01 Doses of 2.0x10° or 2.0x10'° vp per eye’ Adverse Reaction Pts All Grades Grade 23 CTCAE grade N n % n % Uveitis 4 2 50% 2 50% Periphlebitis 4 1 25% 0 0% * VCN-01 was reasonably well tolerated after intravitreal administration?, alth

  42. Slide 42: Retinoblastoma project clinical development

    Retinoblastoma Project Clinical Development * Developing a clinical protocol for an open-label, multinational study * Rb patients with vitreous seeds ° IVit VCN-01 in combination with chemotherapy (no defined SoC) * PI Dr. Guillermo Chantada, MD PhD’ * Status * Clinical study design being discussed

Theriva Biologics — Investor Presentation (November 2023) on 6ix